FDA Approves Tucatinib in Combination with Chemotherapy for HER2-Positive Breast Cancer

The FDA approved tucatinib in combination with chemotherapy for the treatment of adult patients with advanced forms of HER2-positive breast cancer.

Source: CancerNetwork - April 17, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news